Bayer AG (WBO:BAYN) Dividends Received


WBO:BAYN Bayer AG WBO:BAYN
51 GF Score
Price €51.02
GF Value €27.33
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Bayer AG Dividends Received?

Dividends Received only applicable to companies reporting Cash Flow from Operations in direct method.

WBO:BAYN
51GF Score
Bayer AG WBO:BAYN
Dividends Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Bayer AG (WBO:BAYN) Overvalued in 2026?

Based on GuruFocus' analysis, Bayer AG stock appears to be overvalued. The current stock price of €51.02 is trading 86.7% above its estimated GF Value™ of €27.33. GuruFocus considers Bayer AG to be Significantly Overvalued.

Key valuation signals for WBO:BAYN:

  • Dividends Received:
  • GF Value™: €27.33 vs. price of €51.02 (86.7% above fair value)
  • GF Score™: 51/100 with 7 warning signs

No single metric tells the full story. See the WBO:BAYN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Bayer AG Business Description

Address Kaiser-Wilhelm-Allee 1, Leverkusen, NW, DEU, 51368
Bayer is a German healthcare and agriculture conglomerate. Healthcare provides close to half of the company's sales and includes pharmaceutical drugs (about 38% of total sales in 2025) as well as vitamins and other consumer healthcare products (13% of total). The firm's crop science business (47% of total) sells seeds, pesticides, herbicides, and fungicides, which was expanded through its 2018 acquisition of Monsanto.
51GF Score

Get the complete analysis for WBO:BAYN

Dividends Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€51.02
Price
€27.33
GF Value